Effectiveness of Vaccines and Monoclonal Antibodies Against Respiratory Syncytial Virus: Generic Protocol for...

Area of Science:

• Immunology and infectious diseases
• Public health and epidemiology
• Vaccinology

Background:

• Multiple respiratory syncytial virus (RSV) immunization products are in development for key populations, including children, pregnant individuals, and older adults.
• Some RSV vaccines have already gained regulatory authorization, necessitating post-authorization studies.
• Monitoring the real-world effectiveness of these vaccines is crucial for public health decision-making.

Purpose of the Study:

• To introduce a generic protocol designed for register-based cohort studies.
• To facilitate the evaluation of immunization product effectiveness against respiratory syncytial virus (RSV)-specific and non-specific outcomes.
• To support researchers in conducting postmarketing surveillance of RSV vaccines.

Main Methods:

• Development of a standardized, adaptable protocol for register-based cohort studies.
• The protocol is designed to be generic, allowing for application across various healthcare systems and available data sources.
• Utilizes existing healthcare databases and registers for data collection and analysis.

Main Results:

• A comprehensive, generic protocol for postmarketing surveillance of RSV immunization products has been established.
• The protocol enables the assessment of vaccine effectiveness using real-world data from healthcare registers.
• It provides a framework for evaluating both RSV-specific and non-specific health outcomes.

Conclusions:

• The developed generic protocol provides a valuable tool for researchers to conduct robust postmarketing studies on RSV immunization products.
• This framework will aid in monitoring vaccine effectiveness and informing public health strategies.
• The protocol's adaptability to various data sources ensures its wide applicability in different settings.